August 2024 Pharma News Overview: Key Developments in Biosimilars, Obesity, Alzheimer's, and Biotech Financing

Biosimilars

The Federal Trade Commission (FTC) has endorsed the FDA's proposed guidance on interchangeable biosimilar drugs, aimed at enhancing competition in the biologic drug market. The guidance removes the requirement for clinical switching studies for biosimilars to be deemed interchangeable, instead allowing applicants to submit supporting data from existing biologic license applications. This shift is expected to expedite biosimilar approvals, reduce healthcare costs, and improve patient access to lower-cost medications. The FTC highlights the need to monitor anticompetitive practices that could hinder these benefits.

Genchrome Insights: This reform may boost competition and patient access, but it’s crucial to assess its broader business and sustainability impacts. We would advise companies to look at potential benchmark into other countries in Europe to anticipate and mitigate those risks.

Obesity

A recent study published in JAMA Network Open highlights a significant association between semaglutide, a GLP-1 receptor agonist, and increased reports of suicidal ideation, particularly among patients also using antidepressants.No similar association was found with liraglutide, another GLP-1 agonist. The study calls for more research and heightened psychiatric monitoring of semaglutide patients, particularly those with preexisting mental health conditions.

Genchrome Insights: Something to watch, particularly in the context of wide use of GLP-1. We would advise biotech companies developing obesity treatments to incorporate these findings into their development plans.

Inflation Reduction Act (IRA)

The August 15th update on the Inflation Reduction Act (IRA) highlights a significant shift in Medicare's approach to drug pricing. For the first time, Medicare has successfully negotiated substantial discounts, up to 79%, for some of the most commonly prescribed medications. This change, set to take effect in 2026, is expected to save Medicare enrollees $1.5 billion. However, these negotiations pose challenges for the pharmaceutical industry, particularly concerning the impact on innovation and R&D investments. Companies must strategically adapt to navigate this new landscape.

Genchrome Insights: While this reforms will allow substantial savings it would also be important for current and future competitors to understand the impact of those price negotiations and how to prepare for it. It’s critical to integrate IRA-related changes into planning to mitigate future disruptions in the competitive landscape.

Alzheimer

Recent updates on lecanemab (Leqembi), a treatment for early-stage Alzheimer’s disease, highlight contrasting regulatory decisions. On July 25, 2024, the European Medicines Agency (EMA) recommended refusing marketing authorization for lecanemab (Leqembi), citing insufficient benefits relative to its risks, particularly the occurrence of amyloid-related imaging abnormalities (ARIA). Despite this, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) licensed lecanemab, recognizing its ability to modestly slow disease progression. However, on the same day, NICE released draft guidance stating that the benefits do not justify the high costs of treatment, leading to a recommendation against its use in the NHS.

The NICE decision is particularly impactful, as it affects approximately 70,000 adults in England who could have been eligible for treatment. While lecanemab shows promise in delaying cognitive decline by 4 to 6 months, the significant financial burden, including bi-weekly hospital infusions and the need for intensive monitoring, was deemed too high relative to its modest clinical benefits.

Genchrome Insights: All those access questions are critical and need to be anticipated as early as possible in the drug development to avoid a negative outcome with payers as described above. For biotech companies the integration of market access and commercial aspects are critical to integrate all along the clinical development.

Biotech

Biotech financing is beginning to recover after a tough three years. While public markets remain cautious, large funding rounds for later-stage companies, particularly in high-demand areas like immunology and neurology, are on the rise. Corporate venture capital is increasingly important, especially for early-stage companies, contributing to projected biopharma venture financing of $28 billion in 2024.

Corporate venture capital has become increasingly crucial in filling the gap left by traditional VCs, especially in Europe, where there is less access to late-stage funding compared to the United States. Some companies, particularly those in high-demand therapeutic areas, have managed to raise significant funds, benefiting from big pharma's ongoing interest in acquiring promising assets.

However, challenges persist, particularly for smaller and newer companies, as the sector continues to navigate a complex financial landscape.

Genchrome Insights: This is a positive outlook. However, for biotech companies it is important to constantly anticipate ‘big pharma’ needs to ensure readiness for future licensing or M&A.

These shifts present both challenges and opportunities for companies looking to stay ahead. At Genchrome, we continuously monitor these trends and provide actionable insights to help biotech, pharma and investors navigate the complexities of the healthcare landscape. To stay updated on the latest industry news and receive tailored advice, be sure to follow us Genchrome

Contact: [email protected]

#IBD #Biotech #Pharma #Obesity #Alzheimer